Dopaminergic modulation of motor network dynamics in Parkinson's disease

Brain

Volumn 138, Issue 3, 2015, Pages 664-678

  Michely, Jochen ^a,b   Volz, Lukas J ^a,b   Barbe, Michael T ^a,c   Hoffstaedter, Felix ^c,d   Viswanathan, Shivakumar ^a,c   Timmermann, Lars ^a   Eickhoff, Simon B ^c,d   Fink, Gereon R ^a,c   Grefkes, Christian ^a,b,c  

^a UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^b MAX PLANCK INSTITUTE FOR NEUROLOGICAL RESEARCH   (Germany)

^c FORSCHUNGSZENTRUM JÜLICH   (Germany)

^d HEINRICH HEINE UNIVERSITY   (Germany)

Author keywords

Bradykinesia; Dopaminergic medication; Effective connectivity; Higher motor control; Premotor loops

Indexed keywords

DOPAMINE RECEPTOR STIMULATING AGENT; LEVODOPA; OXYGEN;

ADULT; AGED; ARTICLE; BRADYKINESIA; CLINICAL ARTICLE; CONTROLLED STUDY; DOPAMINERGIC MODULATION; DOPAMINERGIC SYSTEM; DYNAMICS; EXECUTIVE FUNCTION; FINGER TAPPING TEST; FUNCTIONAL MAGNETIC RESONANCE IMAGING; HUMAN; MALE; MIDDLE AGED; MOTOR CONTROL; MOTOR CORTEX; MOTOR NETWORK DYNAMICS; MOTOR PERFORMANCE; NEUROMODULATION; PARKINSON DISEASE; PREFRONTAL CORTEX; PREMOTOR CORTEX; PRIORITY JOURNAL; PUTAMEN; SUBCORTEX; SUPPLEMENTARY MOTOR AREA; THALAMUS; BAYES THEOREM; BIOLOGICAL MODEL; BLOOD; BRAIN; BRAIN MAPPING; COMPUTER SIMULATION; DISABILITY; DRUG EFFECTS; FEMALE; IMAGE PROCESSING; NERVE TRACT; NONLINEAR SYSTEM; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; PSYCHOMOTOR PERFORMANCE; REACTION TIME; SEVERITY OF ILLNESS INDEX; VASCULARIZATION;

AGED; BAYES THEOREM; BRAIN; BRAIN MAPPING; COMPUTER SIMULATION; DISABILITY EVALUATION; DOPAMINE AGENTS; FEMALE; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; MALE; MIDDLE AGED; MODELS, NEUROLOGICAL; NEURAL PATHWAYS; NONLINEAR DYNAMICS; OXYGEN; PARKINSON DISEASE; PSYCHOMOTOR PERFORMANCE; REACTION TIME; SEVERITY OF ILLNESS INDEX;

EID: 84927976255     PISSN: 00068950     EISSN: 14602156     Source Type: Journal    
DOI: 10.1093/brain/awu381     Document Type: Article

References (89)

1. Azulay JP, Mesure S, Amblard B, Blin O, Sangla I, Pouget J. Visual control of locomotion in Parkinson's disease. Brain 1999; 122 (Pt 1): 111-20.
2. Beck AT, Steer RA, Brown GK. Manual for the beck depression inventory. 2nd edn. San Antonio, TX: Psychological Corporation; 1996.
3. Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc Ser B (Methodological) 1995; 57: 289-300.
4. Brooks DJ, Piccini P, Turjanski N, Samuel M. Neuroimaging of dys-kinesia. Annals of neurology 2000; 47 (4 Suppl 1): S154-8; discussion S8-9.
5. Brown RG, Marsden CD. Internal versus external cues and the control of attention in Parkinson's disease. Brain 1988; 111 (Pt 2): 323-45.
6. Buhmann C, Glauche V, Sturenburg HJ, Oechsner M, Weiller C, Buchel C. Pharmacologically modulated fMRI-cortical responsiveness to levodopa in drug-naive hemiparkinsonian patients. Brain 2003; 126 (Pt 2): 451-61.
7. Ceballos-Baumann AO. Functional imaging in Parkinson's disease: activation studies with PET, fMRI and SPECT. J Neurol 2003; 250 (Suppl 1): I15-23.
8. Cerasa A, Pugliese P, Messina D, Morelli M, Gioia MC, Salsone M, et al. Prefrontal alterations in Parkinson's disease with levodopa-induced dyskinesia during fMRI motor task. Mov Disord 2012; 27: 364-71.
9. Cieslik EC, Zilles K, Caspers S, Roski C, Kellermann TS, Jakobs O, et al. Is there "one" DLPFC in cognitive action control? Evidence for heterogeneity from co-activation-based parcellation. Cereb Cortex 2013; 23: 2677-89.
10. Cools R. Dopaminergic modulation of cognitive function-implications for L-DOPA treatment in Parkinson's disease. Neurosci Biobehav Rev 2006; 30: 1-23.
11. Cools R, Miyakawa A, Sheridan M, D'Esposito M. Enhanced frontal function in Parkinson's disease. Brain 2010; 133 (Pt 1): 225-33.
12. Damier P. Drug-induced dyskinesias. Curr Opin Neurol 2009; 22: 394-9.
13. Defer GL, Widner H, Marie RM, Remy P, Levivier M. Core assessment program for surgical interventional therapies in Parkinson's disease (CAPSIT-PD). Mov Disord 1999; 14: 572-84.
14. Dirnberger G, Jahanshahi M. Executive dysfunction in Parkinson's disease: a review. J Neuropsychol 2013; 7: 193-224.
15. Elgh E, Domellof M, Linder J, Edstrom M, Stenlund H, Forsgren L. Cognitive function in early Parkinson's disease: a population-based study. Eur J Neurol 2009; 16: 1278-84.
16. Escola L, Michelet T, Macia F, Guehl D, Bioulac B, Burbaud P. Disruption of information processing in the supplementary motor area of the MPTP-treated monkey: a clue to the pathophysiology of akinesia? Brain 2003; 126 (Pt 1): 95-114.
17. Esposito F, Tessitore A, Giordano A, De Micco R, Paccone A, Conforti R, et al. Rhythm-specific modulation of the sensorimotor network in drug-naive patients with Parkinson's disease by levo-dopa. Brain 2013; 136 (Pt 3): 710-25.
18. Fahn S, Elton RL. Unified Parkinson's Disease Rating Scale. In: Fahn S, Marsden CD, Calne D, Goldstein M, editors. Recent developments in Parkinson's Disease. Florham Park, NJ: MacMillan Health Care; 1987. p. 153-63.
19. Fahn S. Parkinson Study G. Does levodopa slow or hasten the rate of progression of Parkinson's disease? J Neurol 2005; 252 (Suppl 4): IV37-42.
20. Farid K, Sibon I, Guehl D, Cuny E, Burbaud P, Allard M. Brain dopaminergic modulation associated with executive function in Parkinson's disease. Mov Disord 2009; 24: 1962-9.
21. Fasano A, Daniele A, Albanese A. Treatment of motor and non-motor features of Parkinson's disease with deep brain stimulation. Lancet Neurol 2012; 11: 429-42.
22. Friston KJ, Harrison L, Penny W. Dynamic causal modelling. Neuroimage 2003; 19: 1273-302.
23. Friston K. SPM Helpline. 2012. Available from: https://www.jiscmail. ac.uk/cgi-bin/webadmin?A2=spm;bebd494.1203.
24. Gauggel S, Rieger M, Feghoff TA. Inhibition of ongoing responses in patients with Parkinson's disease. J Neurol Neurosurg Psychiatry 2004; 75: 539-44.
25. Georgiou N, Bradshaw JL, Iansek R, Phillips JG, Mattingley JB, Bradshaw JA. Reduction in external cues and movement sequencing in Parkinson's disease. J Neurol Neurosurg Psychiatry 1994; 57: 368-70.
26. Godefroy O, Azouvi P, Robert P, Roussel M, LeGall D, Meulemans T, et al. Dysexecutive syndrome: diagnostic criteria and validation study. Ann Neurol 2010; 68: 855-64.
27. Gonzalez-Garcia N, Armony JL, Soto J, Trejo D, Alegria MA, Drucker-Colin R. Effects of rTMS on Parkinson's disease: a longitudinal fMRI study. J Neurol 2011; 258: 1268-80.
28. Grafton ST. Contributions of functional imaging to understanding parkinsonian symptoms. Curr Opin Neurobiol 2004; 14: 715-9.
29. Grefkes C, Eickhoff SB, Nowak DA, Dafotakis M, Fink GR. Dynamic intra-and interhemispheric interactions during unilateral and bilateral hand movements assessed with fMRI and DCM. Neuroimage 2008; 41: 1382-94.
30. Haslinger B, Erhard P, Kampfe N, Boecker H, Rummeny E, Schwaiger M, et al. Event-related functional magnetic resonance imaging in Parkinson's disease before and after levodopa. Brain 2001; 124 (Pt 3): 558-70.
31. Herz DM, Eickhoff SB, Lokkegaard A, Siebner HR. Functional neu-roimaging of motor control in parkinson's disease: a meta-analysis. Hum Brain Mapp 2014a; 35: 3227-37.
32. Herz DM, Siebner HR, Hulme OJ, Florin E, Christensen MS, Timmermann L. Levodopa reinstates connectivity from prefrontal to premotor cortex during externally paced movement in Parkinson's disease. Neuroimage 2014b; 90: 15-23.
33. Herz DM, Haagensen BN, Christensen MS, Madsen KH, Rowe JB, Lokkegaard A, et al. The acute brain response to levodopa heralds dyskinesias in Parkinson disease. Ann Neurol 2014c; 75: 829-36.
34. Hoehn MM, Yahr MD. Parkinsonism: onset, progression and mortality. Neurology 1967; 17: 427-42.
35. Hoffstaedter F, Grefkes C, Zilles K, Eickhoff SB. The "what" and "when" of self-initiated movements. Cereb Cortex 2013; 23: 520-30.
36. Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 1992; 55: 181-4.
37. Hultsch DF, MacDonald SW, Dixon RA. Variability in reaction time performance of younger and older adults. J Gerontol B Psychol Sci Soc Sci 2002; 57: P101-15.
38. Iravani MM, McCreary AC, Jenner P. Striatal plasticity in Parkinson's disease and L-dopa induced dyskinesia. Parkinsonism Rel Disord 2012; 18 (Suppl 1): S123-5.
39. Jahanshahi M, Brown RG, Marsden CD. Simple and choice reaction time and the use of advance information for motor preparation in Parkinson's disease. Brain 1992; 115 (Pt 2): 539-64.
40. Jahanshahi M, Jenkins IH, Brown RG, Marsden CD, Passingham RE, Brooks DJ. Self-initiated versus externally triggered movements. I. An investigation using measurement of regional cerebral blood flow with PET and movement-related potentials in normal and Parkinson's disease subjects. Brain 1995; 118 (Pt 4): 913-33.
41. Jahanshahi M, Jones CR, Zijlmans J, Katzenschlager R, Lee L, Quinn N, et al. Dopaminergic modulation of striato-frontal connectivity during motor timing in Parkinson's disease. Brain 2010; 133 (Pt 3): 727-45.
42. Jankovic J. Parkinson's disease: clinical features and diagnosis. J Neurol Neurosurg Psychiatry 2008; 79: 368-76.
43. Jenkinson N, Brown P. New insights into the relationship between dopamine, beta oscillations and motor function. Trends Neurosci 2011; 34: 611-8.
44. Kahan J, Urner M, Moran R, Flandin G, Marreiros A, Mancini L, et al. Resting state functional MRI in Parkinson's disease: the impact of deep brain stimulation on 'effective' connectivity. Brain 2014; 137 (Pt 4): 1130-44.
45. Kalbe E, Calabrese P, Kohn N, Hilker R, Riedel O, Wittchen HU, et al. Screening for cognitive deficits in Parkinson's disease with the Parkinson neuropsychometric dementia assessment (PANDA) instrument. Parkinsonism Rel Disord 2008; 14: 93-101.
46. Kehagia AA, Barker RA, Robbins TW. Neuropsychological and clinical heterogeneity of cognitive impairment and dementia in patients with Parkinson's disease. Lancet Neurol 2010; 9: 1200-13.
47. Koch G. rTMS effects on levodopa induced dyskinesias in Parkinson's disease patients: searching for effective cortical targets. Restor Neurol Neurosci 2010; 28: 561-8.
48. Majsak MJ, Kaminski T, Gentile AM, Flanagan JR. The reaching movements of patients with Parkinson's disease under self-determined maximal speed and visually cued conditions. Brain 1998; 121 (Pt 4): 755-66.
49. Mak MK, Hui-Chan CW. Audiovisual cues can enhance sit-to-stand in patients with Parkinson's disease. Mov Disord 2004; 19: 1012-9.
50. Mallol R, Barros-Loscertales A, Lopez M, Belloch V, Parcet MA, Avila C. Compensatory cortical mechanisms in Parkinson's disease evidenced with fMRI during the performance of pre-learned sequential movements. Brain Res 2007; 1147: 265-71.
51. Marsh L, Biglan K, Gerstenhaber M, Williams JR. Atomoxetine for the treatment of executive dysfunction in Parkinson's disease: a pilot open-label study. Mov Disord 2009; 24: 277-82.
52. Marsh L, McDonald WM, Cummings J, Ravina B. Depression NNWGo, Parkinson's DProvisional diagnostic criteria for depression in Parkinson's disease: report of an NINDS/NIMH Work Group. Mov Disord 2006; 21: 148-58.
53. Martin JP. The basal ganglia and posture. London: Pitman Medical; 1967.
54. Mattay VS, Tessitore A, Callicott JH, Bertolino A, Goldberg TE, Chase TN, et al. Dopaminergic modulation of cortical function in patients with Parkinson's disease. Ann Neurol 2002; 51: 156-64.
55. Michely J, Barbe MT, Hoffstaedter F, Timmermann L, Eickhoff SB, Fink GR, et al. Differential effects of dopaminergic medication on basic motor performance and executive functions in Parkinson's disease. Neuropsychologia 2012; 50: 2506-14.
56. Moisa M, Siebner HR, Pohmann R, Thielscher A. Uncovering a context-specific connectional fingerprint of human dorsal premotor cortex. J Neurosci 2012; 32: 7244-52.
57. Narayanan NS, Rodnitzky RL, Uc EY. Prefrontal dopamine signaling and cognitive symptoms of Parkinson's disease. Rev Neurosci 2013; 24: 267-78.
58. Nieuwboer A, Kwakkel G, Rochester L, Jones D, van Wegen E, Willems AM, et al. Cueing training in the home improves gait-related mobility in Parkinson's disease: the RESCUE trial. J Neurol Neurosurg Psychiatry 2007; 78: 134-40.
59. Nishitani N, Hari R. Temporal dynamics of cortical representation for action. Proc Natl Acad Sci USA 2000; 97: 913-8.
60. Obeso I, Wilkinson L, Casabona E, Bringas ML, Alvarez M, Alvarez L, et al. Deficits in inhibitory control and conflict resolution on cognitive and motor tasks in Parkinson's disease. Exp Brain Res 2011; 212: 371-84.
61. Oldfield RC. The assessment and analysis of handedness: the Edinburgh inventory. Neuropsychologia 1971; 9: 97-113.
62. Passingham RE, Toni I. Contrasting the dorsal and ventral visual systems: guidance of movement versus decision making. Neuroimage 2001; 14 (1 Pt 2): S125-31.
63. Penny WD, Stephan KE, Mechelli A, Friston KJ. Modelling functional integration: a comparison of structural equation and dynamic causal models. Neuroimage 2004; 23 (Suppl 1): S264-74.
64. Postuma RB, Dagher A. Basal ganglia functional connectivity based on a meta-analysis of 126 positron emission tomography and functional magnetic resonance imaging publications. Cereb Cortex 2006; 16: 1508-21.
65. Power JD, Barnes KA, Snyder AZ, Schlaggar BL, Petersen SE. Spurious but systematic correlations in functional connectivity MRI networks arise from subject motion. Neuroimage 2012; 59: 2142-54.
66. Redgrave P, Rodriguez M, Smith Y, Rodriguez-Oroz MC, Lehericy S, Bergman H, et al. Goal-directed and habitual control in the basal ganglia: implications for Parkinson's disease. Nat Rev Neurosci 2010; 11: 760-72.
67. Rowe JB. Connectivity analysis is essential to understand neurological disorders. Front Syst Neurosci 2010; 4pii: 144.
68. Rowe J, Stephan KE, Friston K, Frackowiak R, Lees A, Passingham R. Attention to action in Parkinson's disease: impaired effective connectivity among frontal cortical regions. Brain 2002; 125 (Pt 2): 276-89.
69. Rowe JB, Hughes L, Ghosh BC, Eckstein D, Williams-Gray CH, Fallon S, et al. Parkinson's disease and dopaminergic therapy-differential effects on movement, reward and cognition. Brain 2008; 131 (Pt 8): 2094-105.
70. Rowe JB, Hughes LE, Barker RA, Owen AM. Dynamic causal modelling of effective connectivity from fMRI: are results reproducible and sensitive to Parkinson's disease and its treatment? Neuroimage 2010; 52: 1015-26.
71. Rowe JB, Siebner HR. The motor system and its disorders. Neuroimage 2012; 61: 464-77.
72. Sabatini U, Boulanouar K, Fabre N, Martin F, Carel C, Colonnese C, et al. Cortical motor reorganization in akinetic patients with Parkinson's disease: a functional MRI study. Brain 2000; 123 (Pt 2): 394-403.
73. Samuel M, Ceballos-Baumann AO, Blin J, Uema T, Boecker H, Passingham RE, et al. Evidence for lateral premotor and parietal overactivity in Parkinson's disease during sequential and bimanual movements. A PET study. Brain 1997; 120 (Pt 6): 963-76.
74. Satterthwaite TD, Elliott MA, Gerraty RT, Ruparel K, Loughead J, Calkins ME, et al. An improved framework for confound regression and filtering for control of motion artifact in the preprocessing of resting-state functional connectivity data. Neuroimage 2013; 64: 240-56.
75. Schmitt FA, Farlow MR, Meng X, Tekin S, Olin JT. Efficacy of riv-astigmine on executive function in patients with Parkinson's disease dementia. CNS Neurosci Ther 2010; 16: 330-6.
76. Siegert RJ, Harper DN, Cameron FB, Abernethy D. Self-initiated versus externally cued reaction times in Parkinson's disease. J Clin Exp Neuropsychol 2002; 24: 146-53.
77. Souques AA. Older description of parkinsonian persons who can run much easier than walk. Revue Neurologique (Paris) 1921; 37: 559-60.
78. Stephan KE, Penny WD, Moran RJ, den Ouden HE, Daunizeau J, Friston KJ. Ten simple rules for dynamic causal modeling. Neuroimage 2010; 49: 3099-109.
79. Taniwaki T, Okayama A, Yoshiura T, Nakamura Y, Goto Y, Kira J, et al. Reappraisal of the motor role of basal ganglia: a functional magnetic resonance image study. J Neurosci 2003; 23: 3432-8.
80. Tomlinson CL, Stowe R, Patel S, Rick C, Gray R, Clarke CE. Systematic review of levodopa dose equivalency reporting in Parkinson's disease. Mov Disord 2010; 25: 2649-53.
81. Vingerhoets FJ, Schulzer M, Calne DB, Snow BJ. Which clinical sign of Parkinson's disease best reflects the nigrostriatal lesion? Ann Neurol 1997; 41: 58-64.
82. Wang LE, Fink GR, Diekhoff S, Rehme AK, Eickhoff SB, Grefkes C. Noradrenergic enhancement improves motor network connectivity in stroke patients. Ann Neurol 2011; 69: 375-88.
83. Werheid K, Koch I, Reichert K, Brass M. Impaired self-initiated task preparation during task switching in Parkinson's disease. Neuropsychologia 2007; 45: 273-81.
84. Witt ST, Laird AR, Meyerand ME. Functional neuroimaging correlates of finger-tapping task variations: an ALE meta-analysis. Neuroimage 2008; 42: 343-56.
85. Wu T, Hallett M. The cerebellum in Parkinson's disease. Brain 2013; 136 (Pt 3): 696-709.
86. Wu T, Wang L, Hallett M, Chen Y, Li K, Chan P. Effective connectivity of brain networks during self-initiated movement in Parkinson's disease. Neuroimage 2011; 55: 204-15.
87. Wu T, Wang L, Hallett M, Li K, Chan P. Neural correlates of biman-ual anti-phase and in-phase movements in Parkinson's disease. Brain 2010; 133 (Pt 8): 2394-409.
88. Ye Z, Altena E, Nombela C, Housden CR, Maxwell H, Rittman T, et al. Improving response inhibition in Parkinson's disease with ato-moxetine. Biol Psychiatry 2014a, in press.
89. Ye Z, Altena E, Nombela C, Housden CR, Maxwell H, Rittman T, et al. Selective serotonin reuptake inhibition modulates response inhibition in Parkinson's disease. Brain 2014b; 137 (Pt 4): 1145-55.